Dr. Betty Hamilton on Molecular Mutations in AML and MDS

Betty Hamilton, MD, assistant professor, Cleveland Clinic, discusses TET2 mutations in molecular mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) on allogeneic hematopoietic cell transplant (HCT) outcomes. Hamilton says that determining molecular mutations in patients with AML or MDS is becoming an increasingly powerful tool in determining the proper path of treatment.